Bristol-Myers Offers Update On Ongoing Regulatory Review Of Opdivo Plus Low-Dose Yervoy In First-Line Lung Cancer Patients With Tumor Mutational Burden: CHMP Requested Added Info From CheckMate -227
Benzinga Newsdesk